HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMPs comment deadline extended

This article was originally published in The Tan Sheet

Executive Summary

FDA will allow until August 11 for interested parties to submit comments on dietary supplement good manufacturing practices proposed rule, according to notice slated for publication in May 19 Federal Register. Sixty-day extension comes after several trade groups requested additional time to look at the economic impact of the proposed reg, especially as it will relate to small businesses 1("The Tan Sheet" May 12, 2003, p. 15)...

You may also be interested in...



Supplement Marketer/Supplier Increased Collaboration On Science Predicted

Partnerships between dietary supplement suppliers and manufacturers will accelerate in the near future to help enhance research capabilities and consumer marketing and education efforts, Integrated Marketing Group President Jeff Hilton predicted at Supply Side East in Secaucus, N.J. May 7

Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel